StockWatch
·
Laboratory Analytical Instruments
PartnershipJul 13, 2026, 12:53 PM

Alamar Biosciences Launches National Alzheimer's Proteomics Program

AI Summary

Alamar Biosciences, Inc. announced a national proteomics program in collaboration with leading research universities to accelerate biomarker discovery and validation for Alzheimer's disease and related neurodegenerative disorders. The program will analyze approximately 21,000 plasma samples from 10,000 participants using Alamar's NULISAseq™ Neuro 220 multiplex assay kit, including a new eMTBR-Tau assay. All generated data will be open-access, linked via NACC identifiers, and will support AI-led exploration and a national data challenge.

Key Highlights

  • Alamar Biosciences partners with top universities for national proteomics program.
  • Program to analyze approximately 21,000 plasma samples from 10,000 ADRC participants.
  • Utilizes Alamar's NULISAseq™ Neuro 220 multiplex assay kit for analysis.
  • Includes new eMTBR-Tau assay for T-protein tangles and neurodegeneration biomarkers.
  • Generated data will be open-access and linked via National Alzheimer’s Coordinating Center identifiers.
  • Aims to accelerate Alzheimer's and related neurodegenerative disease biomarker discovery.
  • Part of the CLARiTI initiative, supported by Alzheimer’s Association and Robertson Foundation.